Literature DB >> 6361299

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

.   

Abstract

The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a multicenter, randomized, double-blind study, tested the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD) in 3,806 asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia). The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7.4 years. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol (LDL-C) reductions of 13.4% and 20.3%, respectively, which were 8.5% and 12.6% greater reductions than those obtained in the placebo group. The cholestyramine group experienced a 19% reduction in risk (p less than .05) of the primary end point--definite CHD death and/or definite nonfatal myocardial infarction--reflecting a 24% reduction in definite CHD death and a 19% reduction in nonfatal myocardial infarction. The cumulative seven-year incidence of the primary end point was 7% in the cholestyramine group v 8.6% in the placebo group. In addition, the incidence rates for new positive exercise tests, angina, and coronary bypass surgery were reduced by 25%, 20%, and 21%, respectively, in the cholestyramine group. The risk of death from all causes was only slightly and not significantly reduced in the cholestyramine group. The magnitude of this decrease (7%) was less than for CHD end points because of a greater number of violent and accidental deaths in the cholestyramine group. The LRC-CPPT findings show that reducing total cholesterol by lowering LDL-C levels can diminish the incidence of CHD morbidity and mortality in men at high risk for CHD because of raised LDL-C levels. This clinical trial provides strong evidence for a causal role for these lipids in the pathogenesis of CHD.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6361299     DOI: 10.1001/jama.1984.03340270029025

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  433 in total

Review 1.  Knowledge, patterns of care, and outcomes of care for generalists and specialists.

Authors:  L R Harrold; T S Field; J H Gurwitz
Journal:  J Gen Intern Med       Date:  1999-08       Impact factor: 5.128

Review 2.  The interpretation and clinical application of data from trials on sudden cardiac death.

Authors:  R J Myerburg; R Mitrani; A Interian; J Simmons; M Kloosterman; A Castellanos
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

Review 3.  The effects of information framing on the practices of physicians.

Authors:  P McGettigan; K Sly; D O'Connell; S Hill; D Henry
Journal:  J Gen Intern Med       Date:  1999-10       Impact factor: 5.128

Review 4.  Pathogenesis and pathology of coronary heart disease syndromes.

Authors:  P M Ridker; E M Antman
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

Review 5.  New developments in atherosclerosis imaging: electron beam tomography.

Authors:  H S Hecht
Journal:  Curr Atheroscler Rep       Date:  2001-09       Impact factor: 5.113

6.  Fillers can transform people's lives.

Authors:  J Le Fanu
Journal:  BMJ       Date:  2001-04-21

Review 7.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 8.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

9.  The 4S study and its pharmacoeconomic implications.

Authors:  J P Reckless
Journal:  Pharmacoeconomics       Date:  1996-02       Impact factor: 4.981

Review 10.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.